S-1 therapy
Phase 2Small molecule
S-1 therapy is one of 6 small molecule programs targeting Postoperative Adjuvant Therapy. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Postoperative Adjuvant Therapy
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Beyfortus
BeiGenePhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Donafenib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Iruplinalkib
Qilu Pharmaceutical Co., Ltd.Phase 2
S-1 therapy
FFirst Affiliated Hospital of Wenzhou Medical University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Maintenance Treatment1 trial
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT03700333·120 enrolled
Postoperative Adjuvant Therapy1 trial
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT06238167·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S-1 therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details